“Our rise reflects years of commitment to building a truly comprehensive cancer center where scientific discovery and exceptional patient care advance hand in hand,” said Stephen D. Nimer, M.D., director of Sylvester. He said the center’s multidisciplinary teams are increasingly equipped to deliver experimental therapies and specialized treatments to patients with complex or difficult-to-treat cancers. This model links laboratory research with clinical practice, allowing discoveries in areas such as tumor biology, molecular diagnostics and therapeutic development to move more efficiently toward patient care.

Sylvester is the only National Cancer Institute-designated cancer center in South Florida, a designation that recognizes institutions with substantial research activity, advanced cancer programs and a commitment to reducing the burden of cancer. Its work spans basic science, population research, clinical investigation and direct treatment. This integrated structure is designed to improve the accuracy of diagnosis, identify biological differences between tumors and match patients with therapies that are more precisely suited to the molecular characteristics of their disease.

A central component of that effort is Sylvester’s academic Phase 1 Clinical Trials Program, described as the only program of its kind in South Florida. Phase 1 trials are generally the first studies in which a new drug, biologic therapy or treatment combination is tested in people. Researchers primarily evaluate safety, tolerability, dosage and how the treatment behaves in the body, although early signals of effectiveness may also emerge. For patients whose cancers have resisted standard therapies, these studies can provide access to treatments years before they become broadly available, while generating data needed for later-stage clinical development.

The center’s research capacity expanded substantially with the opening of the 12-story Kenneth C. Griffin Cancer Research Building in 2025. The facility doubled Sylvester’s research space and brought scientists, physicians, clinical investigators and data specialists into closer proximity. Such physical and organizational integration is important in translational medicine, which seeks to convert discoveries from laboratory models into diagnostic tools, clinical trials and treatments. Shared research environments can accelerate the analysis of tumor samples, the testing of candidate therapies and the development of data-driven approaches to predicting treatment response.

Sylvester is also extending cancer research and prevention beyond its main clinical facilities. Its Game Changer mobile program brings cancer screening, education and research opportunities to medically underserved communities across South Florida. Mobile outreach can help reduce barriers related to transportation, geography and access to specialty care, while screening programs may identify disease at earlier and more treatable stages. The center also leads a nationally recognized firefighter cancer initiative focused on research, prevention, screening and advocacy, addressing occupational exposures and other factors that may influence cancer risk in firefighting populations.

Additional programs target cancer survivorship and prevention. An NCI-funded effort is working to strengthen survivorship care through community health centers, where patients may receive long-term monitoring and support closer to home after completing treatment. Sylvester is also advancing lifestyle medicine and research on human papillomavirus-associated cancers. HPV can contribute to the development of several malignancies, including cervical, anal, oropharyngeal and other cancers. Combining vaccination, screening, behavioral interventions and molecular research may help reduce preventable disease and improve outcomes for people already diagnosed.

The latest rankings reflect performance across the wider UHealth system as well. Four additional programs earned national rankings, including ophthalmology, neurology and neurosurgery, geriatrics, and cardiology, heart and vascular surgery. Bascom Palmer Eye Institute retained the nation’s No. 1 position in ophthalmology for the 25th consecutive year. UHealth’s neurology and neurosurgery program ranked No. 14 nationally and includes more than 70 research and clinical faculty working across neurological subspecialties. Five other specialties—urology, diabetes and endocrinology, gastroenterology and gastrointestinal surgery, orthopedics, and pulmonology and lung surgery—received high-performing designations, placing them among the top 10% of hospitals nationwide.

Together, the results point to an expanding health system built around specialized care, research infrastructure and long-term patient management. “We are proud of what these results say about our progress, but our focus remains on what comes next,” said Dipen J. Parekh, M.D., chief executive officer of UHealth. He said the system would continue investing in people, innovation and specialized services. For Sylvester, the national rise is both a measure of recent progress and a sign of the competitive importance of connecting advanced cancer biology, early-phase clinical research, community prevention and comprehensive care within a single academic health system.

Subject of Research: Cancer research, clinical oncology, cancer prevention, Phase 1 clinical trials and translational medicine.

Article Title: Sylvester Cancer Center Rises to No. 23 Nationwide in 2026 U.S. News Rankings

News Publication Date: August 4, 2026

Web References: Sylvester Comprehensive Cancer Center: https://umiamihealth.org/en/sylvester-comprehensive-cancer-center; Kenneth C. Griffin Cancer Research Building: https://umiamihealth.org/en/locations/sylvester-comprehensive-cancer-center-kenneth-c-griffin-cancer-research-building; UHealth rankings report: https://news.med.miami.edu/uhealth-highest-us-news-hospital-rankings-2026/

References: U.S. News & World Report 2026 Best Hospitals rankings; National Cancer Institute cancer center designation information; Sylvester Comprehensive Cancer Center announcement.

Image Credits: Sylvester Comprehensive Cancer Center

Keywords: Cancer, cancer research, clinical research, oncology, Phase 1 clinical trials, translational medicine, Sylvester Comprehensive Cancer Center, UHealth, University of Miami, National Cancer Institute, cancer prevention, survivorship care

AMP represents molecular diagnostics professionals and clinical laboratory scientists who develop and perform tests that inform diagnosis, treatment selection, and disease monitoring. For this year’s award, the committee highlighted Jaffe’s sustained influence on how molecular findings are translated into clinical decisions.

Jaffe’s work has reshaped scientific and medical understanding of lymphoid malignancies, particularly by defining lymphomas as distinct diseases of the immune system rather than broad, histologic categories. Her contributions helped build modern frameworks that guide prognosis and research directions worldwide.

A central part of her legacy is the molecular dissection of T-cell, B-cell, and natural killer-cell lymphomas. By connecting molecular mechanisms to disease behavior, her research provided a clearer biological basis for classification, risk assessment, and patient stratification.

Her investigations into Epstein–Barr virus–associated disorders further broadened hematopathology’s molecular scope. In parallel, studies related to Castleman disease and immune dysregulation syndromes expanded understanding of how immune perturbations drive malignancy.

AMP leadership noted that Jaffe’s efforts profoundly shaped global clinical practice. The committee emphasized her role in harmonizing lymphoma diagnosis through World Health Organization and International Consensus Classification systems—tools now used across laboratories and countries.

According to AMP President Aaron Bossler, M.D., Ph.D., the recognition also reflects the association’s mission to advance molecular technologies for better patient care. Jaffe is widely cited in clinical oncology and has served as a senior investigator at NCI since 1974.

Her academic path included degrees from Cornell University and the University of Pennsylvania School of Medicine, with residencies at Georgetown University Hospital and NCI. In 1974, her team published work identifying follicular lymphoma as arising from germinal center tissue in the New England Journal of Medicine, often described as a “citation classic.”

Jaffe will receive the award and deliver a lecture on Nov. 12 during the AMP 2026 Annual Meeting & Expo in Seattle.

Subject of Research: Molecular diagnostics in lymphoid malignancies (lymphomas)
Article Title: Elaine S. Jaffe Wins AMP 2026 Award for Excellence in Molecular Diagnostics
News Publication Date: 2026
Web References: www.amp.org
References: New England Journal of Medicine (1974 paper on follicular lymphoma as germinal center origin)
Image Credits: Courtesy of Elaine S. Jaffe, M.D.

Keywords: molecular diagnostics, lymphoma classification, molecular underpinnings, WHO classification, immune dysregulation, Epstein–Barr virus, Castleman disease, clinical oncology biomarkers

Nasopharyngeal carcinoma, notorious for its distinct epidemiological and biological characteristics, particularly its strong association with Epstein-Barr virus (EBV), remains a formidable clinical challenge. Conventional treatment paradigms have long relied on radiotherapy combined with chemotherapy; however, prognostic uncertainty often clouds adjuvant therapy decisions post-neoadjuvant chemotherapy. The utilization of plasma EBV DNA as a biomarker, detectable through liquid biopsy techniques, provides clinicians an unprecedented opportunity to monitor real-time tumor dynamics, assess treatment response, and tailor subsequent therapeutic interventions.

Liquid biopsy, leveraging circulating tumor DNA (ctDNA) analysis, represents a leap forward from traditional tissue biopsies that are invasive and often impractical for serial monitoring. In NPC, the quantification of plasma EBV DNA serves as a surrogate marker for tumor burden and residual disease, enabling the stratification of patients based on molecular response profiles. Lam and Ma delineate how integrating this molecular data during neoadjuvant chemotherapy can inform adjuvant decisions, bridging the gap between initial systemic treatment and long-term disease control.

The process begins with baseline EBV DNA quantification, establishing the tumor’s molecular footprint before chemotherapy initiation. As neoadjuvant cycles proceed, serial measurements of plasma EBV DNA provide dynamic insights into tumor cell clearance or persistence. This temporal profiling surpasses conventional imaging by revealing microscopic residual disease that might otherwise evade detection, thereby refining risk assessment and guiding the intensity of adjuvant treatment.

Critically, the application of liquid biopsy in NPC capitalizes on its high specificity due to the virus’s tumor specificity and its release into circulation upon tumor cell apoptosis or necrosis. The authors emphasize that measurable plasma EBV DNA post-neoadjuvant chemotherapy correlates strongly with relapse risk, advocating for intensified adjuvant therapy in this cohort. Conversely, undetectable or significantly reduced EBV DNA might justify de-escalation, sparing patients undue toxicity while maintaining efficacy.

The technological advancements enabling these clinical insights cannot be overstated. Ultra-sensitive quantitative PCR (qPCR) and next-generation sequencing (NGS) platforms have refined the detection thresholds of ctDNA, facilitating accurate quantification of plasma EBV DNA even at minimal residual disease levels. Lam and Ma discuss how these methodologies, combined with rigorous assay standardization, underpin the reliability of liquid biopsy as a clinical decision-support tool in NPC.

However, challenges remain in the broader implementation of this paradigm. Biological heterogeneity, variability in viral shedding, and the influence of host immune response may introduce complexity in interpreting plasma EBV DNA kinetics. The authors advocate for prospective clinical trials incorporating liquid biopsy-guided adjuvant strategies, to validate prognostic thresholds and optimize treatment algorithms tailored to molecular responses.

Intriguingly, the concept of a “full-circle” moment proposed by the authors alludes to the origin of NPC diagnosis, where EBV serology and plasma DNA have historically played a diagnostic role, now coming full circle to guide post-neoadjuvant treatment. This cyclic integration underscores the maturation of precision oncology, leveraging molecular biomarkers from diagnosis through to adjuvant decision-making.

Moreover, this strategy holds promise beyond NPC, serving as a model for other virus-associated or molecularly defined cancers whereby tumor-derived nucleic acid in plasma can provide real-time insights into treatment efficacy. The ability to interrupt the treatment pathway based on sensitive molecular monitoring heralds an adaptive therapeutic framework, enhancing clinical outcomes while minimizing unnecessary toxicity.

Lam and Ma also touch upon the potential for combining plasma EBV DNA data with emerging immunotherapeutic approaches. Given the immunogenicity of EBV-related NPC, liquid biopsy might serve to identify patients likely to benefit from immune checkpoint inhibitors or adoptive cell therapies, thereby integrating molecular monitoring with novel systemic treatments.

The implications for healthcare delivery are profound. Liquid biopsy-guided adjuvant therapy decisions could streamline patient management, reducing reliance on imaging modalities and invasive biopsies, while allowing personalized treatment intensification or de-escalation grounded in robust molecular evidence. This holds particularly true for resource-limited settings where NPC is endemic, where plasma-based assays might represent accessible tools for optimized care.

In summary, this perspective heralds a paradigm shift in NPC management, where liquid biopsy is not merely a diagnostic adjunct but a central component in guiding adjuvant therapy post-neoadjuvant chemotherapy. The full realization of this approach demands multidisciplinary collaboration, ongoing technological refinement, and concerted clinical research efforts to translate molecular insights into tangible survival benefits.

As the frontier of oncology advances towards more individualized and dynamic treatment paradigms, the integration of liquid biopsy into NPC care pathways epitomizes precision medicine in action. The journey from molecular discovery to clinical application encapsulated in this “full-circle” moment exemplifies the potential of translational research to reshape cancer therapeutics and improve patient outcomes fundamentally.

The coming years will undoubtedly witness expanded incorporation of liquid biopsy technologies, with NPC serving as a vanguard model. The ability to non-invasively track tumor evolution, adapt therapy accordingly, and provide prognostic clarity may well extend the paradigm to a broader spectrum of malignancies, redefining standards of care across oncology.

This paradigm also fuels optimism for curing a cancer historically burdened by late diagnosis and complex management. By harnessing the molecular signals embedded within plasma, clinicians can anticipate a future where treatment regimens are responsive, evidence-driven, and uniquely tailored to the biology of each patient’s disease trajectory.

Lam and Ma’s work lays foundational insights, urging the oncology community to embrace liquid biopsy-driven approaches, capitalizing on molecular precision to inform and harmonize therapeutic decisions. This full-circle integration, encapsulated in the context of nasopharyngeal carcinoma, illuminates a promising horizon where liquid biopsy transcends research tools to become indispensable clinical assets.

Subject of Research: Liquid biopsy application in nasopharyngeal carcinoma to guide adjuvant therapy decisions during neoadjuvant chemotherapy.

Article Title: Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy — a full-circle moment for nasopharyngeal cancer.

Article References:
Lam, W.K.J., Ma, B.B.Y. Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy — a full-circle moment for nasopharyngeal cancer. Nat Rev Clin Oncol (2026). https://doi.org/10.1038/s41571-026-01157-8

Image Credits: AI Generated

At the forefront of NPC detection are plasma EBV DNA assays, utilizing polymerase chain reaction (PCR) technology to identify low levels of viral DNA circulating in the blood. This approach has demonstrated remarkable sensitivity in uncovering NPC cases well before overt clinical symptoms manifest. By capturing the disease at an asymptomatic or early stage, plasma EBV DNA screening holds promise for initiating timely intervention, which can significantly enhance survival rates. The power of this biomarker stems from its direct association with tumor-derived EBV DNA, reflecting the tumor burden and allowing dynamic monitoring.

More recent innovations have focused on a refined analysis of plasma EBV DNA, known as fragmentomics, where the size and fragmentation patterns of viral DNA fragments are studied. This sophisticated technique improves test specificity by distinguishing between EBV DNA fragments emanating from malignant cells versus those released by benign or latent infections. Such discriminative capacity not only reduces false positives but also offers predictive insight by stratifying individuals according to their future NPC risk. The implications of fragmentomic profiling are profound, suggesting that routine EBV DNA screening could evolve into a finely tuned surveillance tool with personalized risk assessment.

In parallel with DNA-based diagnostics, serological screening methods targeting EBV-specific antibodies have been rigorously validated. Initial strategies detected immunoglobulin A (IgA) antibodies against the EBV viral capsid antigen (VCA) and Epstein–Barr nuclear antigen 1 (EBNA1), which formed the cornerstone of NPC screening programs in endemic areas. Large-scale prospective studies have confirmed that these antibody assays can effectively identify individuals at elevated risk for NPC, ultimately correlating with reductions in disease-specific mortality. This serological approach benefits from its relative ease of implementation and has served as a foundation for population-wide screening initiatives.

Further refinement in antibody-based screening emerged with the recognition of anti-BNLF2b antibodies as critical serological markers. Clinical data indicate that detecting these antibodies alone yields higher sensitivity and specificity compared to the previous dual-antibody method. This discovery optimizes the diagnostic algorithm and streamlines the screening process, minimizing unnecessary follow-ups due to false-positive results. The utilization of anti-BNLF2b antibodies presents a crucial advancement in serodiagnostics, enhancing early NPC detection and supporting improved preventative healthcare strategies in high-risk populations.

Economically, rigorous cost-effectiveness analyses advocate for the implementation of EBV DNA and antibody-based NPC screening programs in regions where the disease is endemic. These studies illustrate that early detection facilitated by these biomarkers can reduce the overall economic burden by decreasing treatment costs related to advanced disease stages and minimizing productivity loss. Health policymakers are encouraged to consider integrating these screening modalities within existing healthcare infrastructures to maximize societal benefits and improve clinical outcomes over time.

Looking beyond diagnostics, the horizon now includes the development of prophylactic and therapeutic vaccines against EBV, targeting the root cause of NPC and other EBV-associated malignancies. Vaccine research aims to harness immunological tools to prevent primary EBV infection or modify its oncogenic potential, potentially disrupting the natural history of disease progression. Such vaccines carry the prospect of not only controlling NPC incidence but also significantly reducing the global burden of EBV-related cancers and diseases, marking a transformative leap from treatment to true prevention.

Despite substantial progress, significant challenges remain in optimizing NPC management through EBV-based approaches. For plasma EBV DNA testing, ensuring standardization across laboratories and refining the interpretation of fragmentomics data are critical steps to maximize clinical utility. Antibody-based assays require continual validation across diverse populations and integration with confirmatory diagnostic pathways to prevent missed or delayed diagnoses. Moreover, vaccine development faces hurdles related to antigen selection, immune response durability, and widespread applicability, necessitating sustained investment in research and clinical trials.

The integration of EBV biomarkers into liquid biopsy platforms heralds a promising frontier for NPC screening and may extend to other EBV-associated cancers as well. Insights gained from NPC research provide a valuable framework for liquid biopsy innovations, where minimally invasive blood-based testing can revolutionize early detection and risk stratification across oncology. By exploiting the viral signature within circulating DNA and antibodies, clinicians can envision a future where cancer screening is more accurate, convenient, and personalized, ultimately enhancing patient survival and quality of life.

In the public health domain, the implementation of EBV-based NPC screening programs reflects a model of targeted cancer control in populations with a high prevalence of viral oncogenesis. This approach underlines the importance of epidemiological understanding and molecular technology synergy in disease prevention. Coordinated screening efforts that combine EBV DNA and serological testing, coupled with appropriate confirmatory diagnostics, yield the best prospects for curbing the incidence and mortality of NPC.

The promise of NPC vaccines lies not only in preventing the emergence of this carcinoma but also in reducing the global incidence of EBV-related diseases such as Hodgkin lymphoma and gastric carcinoma. Advances in vaccine platforms—including viral vector vaccines, subunit vaccines, and novel adjuvants—have accelerated preclinical and clinical development pipelines. Immunogenicity studies are underway to identify optimal formulations capable of eliciting robust and durable antiviral immune responses.

To translate these advances from bench to bedside, multidisciplinary collaborations encompassing virology, oncology, epidemiology, and immunology are essential. Governmental and international agencies must also align funding and regulatory frameworks to accelerate the availability of EBV-targeted vaccines and screening technologies, particularly in underserved regions bearing the highest NPC burden.

In conclusion, the convergence of molecular diagnostics, serological biomarkers, and vaccine development crystallizes a comprehensive strategy against nasopharyngeal carcinoma. By exploiting the pathological nexus between EBV infection and NPC carcinogenesis, healthcare systems in endemic regions stand at a transformative juncture where early detection and primary prevention could dramatically alter disease trajectories. This evolving landscape offers hope not only for patients grappling with NPC but also provides an illuminating example of viral oncology’s impact on global cancer control efforts.

Subject of Research: Nasopharyngeal carcinoma and Epstein–Barr virus-based screening and vaccination strategies

Article Title: Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines

Article References:
Lam, W.K.J., Ma, B.B.Y., King, A.D. et al. Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines. Nat Rev Clin Oncol (2025). https://doi.org/10.1038/s41571-025-01079-x

Image Credits: AI Generated

Bladder cancer remains a formidable clinical challenge due to its heterogeneous nature and variable response to therapy. Precise molecular characterization of tumor samples is crucial for tailored treatment strategies. The FRS2 gene, implicated in multiple signaling pathways that regulate cellular proliferation and differentiation, has recently emerged as a key biomarker. Detecting copy number variations of FRS2 can yield critical insights into tumor biology and guide therapeutic decisions. However, conventional detection methods, such as fluorescence in situ hybridization (FISH), although specific, often lack the quantitative resolution and throughput necessary for routine clinical application.

The research team embarked on designing a ddPCR assay, capitalizing on its ability to provide absolute quantification of nucleic acids without reference to standard curves. Using FFPE bladder cancer samples, which are notoriously challenging due to DNA degradation and cross-linking, the assay was validated for sensitivity, specificity, and dynamic range. Employing FRS2 as the target gene and RPP30 as a single-copy reference gene, the researchers optimized primer and probe sets to enable duplex detection within a single reaction, thus improving assay efficiency and reducing sample consumption.

A critical milestone was the assay’s performance in discriminating positive from negative droplets. One-dimensional fluorescence amplitude plots demonstrated distinct separation between droplets containing the FRS2 and RPP30 sequences and those without target DNA, underscoring the assay’s robustness. This clear demarcation is essential for accurate quantification, as ambiguous droplet signals can confound data interpretation and undermine reliability.

Precision studies revealed excellent repeatability, with intra-assay coefficients of variation (CV) ranging from 2.58% to 3.75% across tested DNA input amounts. Inter-assay variability was equally impressive, registering CVs below 4%, affirming the method’s reproducibility. Such consistency is paramount in clinical settings, where diagnostic assays must deliver reliable results across multiple runs and laboratories.

Importantly, the minimal input DNA requirement was determined to be as low as 2 nanograms, a remarkably low threshold given the limited availability of tumor DNA in clinical samples. The assay maintained linearity across a broad concentration range, with correlation coefficients (R²) exceeding 0.99, indicating its suitability for both low and high copy number detection, inclusive of amplification events frequently observed in oncogenes.

Validation against the gold-standard FISH technique showcased the ddPCR assay’s impeccable accuracy. Achieving 100% sensitivity and specificity, along with a perfect kappa value of 1.0, the ddPCR method matched FISH in identifying true positive and negative cases without false results. This equivalence, combined with the advantages of ddPCR in throughput and quantitative output, suggests the assay’s potential to supplant or complement traditional cytogenetic approaches.

The duplex format of the assay, which simultaneously quantifies FRS2 and the reference gene RPP30 within the same tube, eliminates potential inter-sample variability. By normalizing the target gene copy number to a stable reference, the assay mitigates biases arising from DNA quality and quantity fluctuations, thus enhancing confidence in copy number calls, particularly in clinical samples where DNA degradation is common.

Extending beyond technical validation, the assay presents promising applications in bladder cancer diagnosis, stratification, and treatment monitoring. Quantifying FRS2 gene dosage could identify patients harboring gene amplifications associated with aggressive tumor behavior or resistance to conventional therapies. Integrating this molecular metric into clinical workflows may pave the way for personalized medicine approaches, improving patient outcomes through more precise risk assessment.

Furthermore, the utilization of FFPE samples in this assay reflects real-world conditions, as archival tissue specimens are often the primary resource for molecular diagnostics. Overcoming challenges associated with FFPE-derived DNA, such as fragmentation and chemical modifications, demonstrates the assay’s practical relevance and potential for widespread adoption in pathology laboratories.

The deployment of ddPCR technology in this context underscores its versatility and transformative impact on cancer genomics. By enabling absolute quantification without the need for standard curves and offering high sensitivity even with minimal and compromised DNA inputs, ddPCR stands out as a superior alternative to quantitative PCR and other amplification-based methods.

In synthesis, the reported ddPCR assay embodies a significant leap forward in bladder cancer molecular diagnostics. Its combination of analytical rigor, operational efficiency, and clinical applicability embodies the changing landscape of cancer genomics, where precision and scalability are paramount. The meticulous development and validation process ensure that this assay can serve as a reliable tool for researchers and clinicians alike, facilitating nuanced genetic profiling essential for next-generation oncology.

As precision medicine continues to evolve, such innovations are critical in bridging the gap between laboratory research and patient-centered care. The ability to accurately and reproducibly measure gene copy numbers in challenging FFPE samples could unlock new biomarkers and therapeutic targets, ultimately translating into more tailored and effective treatments for bladder cancer patients worldwide.

The implications of this technology extend beyond bladder cancer, offering a methodological blueprint for similar assays targeting diverse genetic alterations across various malignancies. By refining molecular assays to cope with the practical constraints of clinical samples, ddPCR paves the way for broader implementation of genomic diagnostics and personalized oncology.

In conclusion, the ddPCR assay for FRS2 gene copy number quantification epitomizes the synthesis of innovative molecular techniques with clinical imperatives. Its demonstrated precision, sensitivity, and operational advantages position it as a frontrunner in the quest for robust cancer biomarker assays, setting a new standard for genetic analysis in FFPE tissue specimens.

Subject of Research: Development and validation of a droplet digital PCR assay for FRS2 gene copy number quantification in FFPE bladder cancer tissue samples.

Article Title: Droplet digital PCR assay for precise determination of FRS2 gene copy number in bladder cancer.

Article References:
Li, J., Liang, J., Xu, Y. et al. Droplet digital PCR assay for precise determination of FRS2 gene copy number in bladder cancer. BMC Cancer 25, 1211 (2025). https://doi.org/10.1186/s12885-025-14611-0

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14611-0